Parametric Portfolio Associates LLC boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 24.8% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,055,983 shares of the company’s stock after acquiring an additional 408,241 shares during the quarter. Parametric Portfolio Associates LLC owned 0.19% of Eli Lilly and worth $169,207,000 at the end of the most recent reporting period.
Other institutional investors have also recently bought and sold shares of the company. Penserra Capital Management LLC increased its position in Eli Lilly and by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock worth $170,000 after buying an additional 176 shares in the last quarter. Abbrea Capital LLC purchased a new stake in Eli Lilly and in the first quarter worth about $202,000. Great Lakes Advisors LLC increased its position in Eli Lilly and by 63.5% in the first quarter. Great Lakes Advisors LLC now owns 15,847 shares of the company’s stock worth $1,333,000 after buying an additional 6,155 shares in the last quarter. 1st Global Advisors Inc. increased its position in Eli Lilly and by 11.5% in the first quarter. 1st Global Advisors Inc. now owns 32,217 shares of the company’s stock worth $2,710,000 after buying an additional 3,311 shares in the last quarter. Finally, Savant Capital LLC increased its position in Eli Lilly and by 10.8% in the first quarter. Savant Capital LLC now owns 7,525 shares of the company’s stock worth $633,000 after buying an additional 736 shares in the last quarter. Institutional investors own 75.48% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Parametric Portfolio Associates LLC Boosts Position in Eli Lilly and Company (LLY)” was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.chaffeybreeze.com/2017/11/15/parametric-portfolio-associates-llc-boosts-position-in-eli-lilly-and-company-lly.html.
A number of analysts have commented on the company. BMO Capital Markets restated a “sell” rating and issued a $73.00 price target on shares of Eli Lilly and in a research report on Friday, August 4th. TheStreet upgraded Eli Lilly and from a “c+” rating to a “b+” rating in a research report on Tuesday, July 25th. Leerink Swann cut Eli Lilly and from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $93.00 to $90.00 in a research report on Wednesday, July 26th. Cowen and Company reiterated a “buy” rating and set a $95.00 target price on shares of Eli Lilly and in a research report on Wednesday, October 4th. Finally, UBS AG cut Eli Lilly and to a “hold” rating and set a $85.00 target price for the company. in a research report on Wednesday, July 26th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $89.76.
Shares of Eli Lilly and Company (NYSE:LLY) opened at $82.49 on Wednesday. The stock has a market capitalization of $91,236.74, a P/E ratio of 20.26, a PEG ratio of 1.83 and a beta of 0.34. Eli Lilly and Company has a one year low of $64.18 and a one year high of $89.09. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.02. The business had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The company’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same period last year, the company earned $0.88 EPS. sell-side analysts predict that Eli Lilly and Company will post 4.22 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be paid a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.52%. The ex-dividend date of this dividend is Tuesday, November 14th. Eli Lilly and’s payout ratio is 98.58%.
In other news, SVP Alfonso G. Zulueta sold 2,003 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the sale, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 205,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $86.81, for a total value of $17,796,050.00. The disclosure for this sale can be found here. Insiders sold a total of 772,003 shares of company stock valued at $64,837,441 over the last ninety days. Corporate insiders own 0.20% of the company’s stock.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.